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Absolute values are used in the interpre-tation of the fraction of 
exhaled nitric oxide (FeNO), but it has been suggested that equations 
to calculate reference values may be a practical and clinically useful 
approach. We hypothesize that the application of the Lambda-Mu-
Sigma (LMS) method may improve FeNO reference equations and 
their interpretation. Our aims were to develop FeNO reference 
equations with the LMS method and to describe the difference 
between this method and the absolute fixed cut-offs of the current 
recommendations. We utilized the United States National Health and 
Nutrition Examination Surveys 2007–2012 and included healthy 
individuals with no respiratory diseases and blood eosinophils 300/
mm3 (n  8,340). Natural log-transformed FeNO was modeled using 
the LMS method, imbedded in the gener-alized additive models for 
location, scale, and shape models. A set of FeNO reference equations 
was developed. The explanatory variables were sex, age, height, 
smoking habits, and race/ethnicity. A significant proportion of 
individuals with normal FeNO given by the equations were classified 
as having intermediate levels by the current recom-mendations. 
Further lower predicted FeNO compared with previous linear models 
was seen. In conclusion, we suggest a novel model for the prediction 
of reference FeNO values that can contribute to the interpretation of 
FeNO in clinical practice. This approach should be further validated 
in large samples with an objective measurement of atopy and a 
medical diagnosis of asthma and rhinitis.
NEW & NOTEWORTHY Novel reference equations and fraction of
exhaled nitric oxide (FeNO)-predicted values to improve interpreta-
tion of FeNO in clinical practice are presented. These may increase
the accuracy of ruling out airway inflammation in patients with
asthma or suspected asthma.
asthma; exhaled nitric oxide; healthy; reference values
INTRODUCTION
Measurement of the fraction of exhaled nitric oxide (FeNO)
is now recognized as an accurate, reproducible, and noninva-
sive diagnostic test for airway disease and is increasingly used
in clinical practice (6). FeNO primarily signals airway inflam-
mation that is triggered by IL-4 and IL-13 (3). However, FeNO
is influenced by several individual factors, including age,
height, sex, atopy, and smoking habits (15). This is an issue
that makes the adequate interpretation of this diagnostic test
more difficult (39).
A diagnostic test result can be presented in different ways,
for example, in absolute values. However, absolute values are
not commonly used in lung function tests, but in the case of
FeNO, the most recent American Thoracic Society (ATS)
guidelines have suggested their use for interpretation (12).
Specifically, the guidelines state that, in steroid-naïve subjects,
a FeNO of 25 parts per billion (ppb) (20 ppb in children 12
yr old) indicates a low likelihood of eosinophilic inflammation
and corticosteroid responsiveness, whereas a FeNO of 50
ppb (35 ppb in children) indicates a high probability of
eosinophilic airway inflammation. The intermediate FeNO
range of 25–50 ppb (20–35 ppb in children) should be inter-
preted with consideration of the clinical context. However, the
guidelines recognize that these fixed cutoffs are weak recom-
mendations with low quality of evidence (12). One of the
solutions proposed to consider the limitations of absolute
values has been a “personal best” value for FeNO (37). Al-
though this is a strong approach if the objective is to monitor
FeNO, this method cannot be used for the initial assessment of
FeNO in a patient. Furthermore, the personal best values were
shown to be close to, at the time, published reference values
(27). Thus, the use of equations to calculate reference values
may be a more practical and clinically useful approach (24), as
recently shown using multiple linear regression models (41).
However, FeNO does not follow a normal distribution in the
healthy population (15), and the lifetime evolution of FeNO
(17), and the large variation of FeNO in the general population,
contributes to the fact that such models have poor predictive
capability (36). Similar issues were identified in the interpre-
tation of lung function with spirometry (40), which has led to
the development of a new approach by the Global Lung
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Initiative, a European Respiratory Society (ERS) task force.
The Global Lung Initiative used very robust statistical regres-
sion methods (38), the lambda-mu-sigma (LMS) method (9), to
model lung function adjusted for sex, height, and ethnicity. The
resulting powerful reference equations have supported the use
of z-scores and percentiles for the classification of spirometric
parameters (31).
We hypothesize that the application of the LMS method may
improve the quality of reference equations for FeNO, and the
subsequent interpretation of this marker, in a healthy population.
Our aims were 1) to develop reference equations for FeNO with
the LMS method by using data from the National Health and
Nutrition Examination Survey (NHANES) (2007–12), 2) to de-
scribe the difference between the LMS model and the fixed
cutoffs of the 2011 ATS recommendations, and 3) to compare
with previously published multiple linear regression models.
METHODS
Study population. The study population was composed of individ-
uals who participated in the NHANES. The NHANES is a nationally
representative survey of the noninstitutionalized United States civilian
population conducted to evaluate health and nutritional status. In each
survey, participants are selected using a complex stratified multistage,
probability-based sampling design, and information is collected by
standardized household interviews, physical examinations, and testing
of biological samples (10, 13, 19). More details are available at:
https://www.cdc.gov/nchs/nhanes.htm. For this analysis, data from
the NHANES 2007 to 2012 were used. From 30,442 participants aged
6 to 80 yr, we have excluded subjects with asthma, emphysema, or
chronic bronchitis (n  4,938), without valid or reproducible FeNO
measurements (n  9,795), and with a blood eosinophil count 300/
mm3 (n  7,011). Thus, we included respiratory healthy individuals
with a normal blood eosinophil count (n  8,340).
Variables. FeNO measurements were performed with NIOX MINO
(Aerocrine, Solna, Sweden), following ATS/ERS recommendations
(4). In brief, participants were asked to empty their lungs, to place
their mouth on the analyzer’s mouthpiece, and to fill their lungs with
NO-free air. Then, they were asked to blow out all of their air at a
constant flow of 50 ml/s, for 10 s if height was at or above 130 cm and
6 s for those below 130 cm. At least two reproducible measurements
were obtained, defined by if either or both of the first two valid FENO
measurements were below 30 ppb and the measurements were within
2 ppb of each other or if both measurements were over 30 ppb and
within 10% of each other. The following aspects were considered
before FeNO measurements: breathing problem requiring oxygen,
problem taking deep breaths, smoked the last hour before the mea-
surement, strenuous exercise in the last hour, eating and drinking in
the last hour, eating nitrate-rich vegetables and nitrite-rich meats in
the last three hours, and cough, cold, or respiratory illness in the past
seven days. More details can be found online (https://wwwn.cdc.gov/
Nchs/Nhanes/2011-2012/ENX_G.htm).
The mean of two reproducible FeNO measurements was consid-
ered; a value of 3.5 ppb was used if the measurements were below the
detection limit of the device (5 ppb, n  1,690). Age was calculated
with one decimal point as the difference between date of birth and
date of examination in both data sets. The categories in the race/
ethnicity groups were based on the NHANES classification (8). Four
groups were created: non-Hispanic white; non-Hispanic black; Mex-
ican-American (including other Hispanics), and other (multi-racial).
An active smoker was defined as a positive answer to both of the
following questions: “Have you smoked 100 cigarettes during your
lifetime?” and “Do you now smoke cigarettes?”, and a never smoker
was defined as a negative answer to the same questions. Since these
questions were only asked in subjects aged16 yr old, we considered
subjects with an age 16 yr never smokers as well. We have
previously shown that former smokers (positive answer to the first
question and negative to the second) have a FeNO similar to never
smokers, if not presently exposed (18). Thus, only current smoking
was used as explanatory variable in the full data set. However, in the
alternative data set, only never smokers were included since former
smokers seem to be more passively exposed to cigarette smoke (18).
Statistical analysis. Categorical variables are presented as absolute
frequencies and proportions. Mean and standard deviation are pre-
sented for continuous variables. FeNO is presented using geometric
means, given its right-skewed distribution, and was transformed using
the natural logarithm (ln), with 95% confidence interval (95% CI). To
allow the modeling of lnFeNO values and more than one explanatory
variable, we applied the LMS method (9), imbedded in the general-
ized additive models for location, scale, and shape (GAMLSS) mod-
els. GAMLSS is a semiparametric regression-type of statistical model,
which is highly flexible as it relaxes the traditional distributional
assumptions about normality to include even highly skewed and
kurtotic distributions (33). The parameters L, M, and S of the
distribution are interpreted as a participant’s expected mean (M) and
additionally for a participant’s expected coefficient of variation (S)
and skewness (L) (31). A more detailed description of the statistical
methodology is described elsewhere (31, 40). FeNO prediction mod-
els were derived for men and women, respectively, with a fitting
spline curve from the NHANES, with the explanatory variables:
height, age, smoking habits (smoker vs nonsmoker), and ethnicity.
After using the models to predict the FeNO value in a given individ-
ual, it is possible to calculate the upper limit of normal at the 95th
percentile (ULN 95th) and the corresponding z-score, as follows:
ULN 95th exp(ln(M) ln(1 1.645.L.S)/L) and z-score [(mea-
sured/M)L  1]/(L.S) (29). Essentially, the general form is a linear
regression equation with an age-specific correction in the form of the
age-spline. Model selection was based on generalized Akaike infor-
mation criterion (GAIC), an index designed to be an unbiased esti-
mator of the information regarding the model fitting. The model with
the lowest value of GAIC is considered as having the best fit (1) and
was selected as the final model. Worm plots and normal Q-Q visual
inspection were additionally used to assess distribution and density
plots of residuals as a function of age. The GAMLSS package
implemented in R statistical software (version 3.1.1) was used for the
analysis. All other statistical analyses were performed using IBM
SPSS Statistics, version 23.0. A P value of 0.05 was considered as
statistically significant. The proportion of observed FeNO greater than
the predicted ULN 95th was calculated.
We have compared the LMS model with two previously published
models (36, 41) by generating the predicted FeNO and the ULN 95th
for 4 example subjects, 2 men and 2 women, using the age breakpoints
previously described (17) and with the mean height in each age strata.
Ethics. The NHANES studies were approved by the ethics com-
mittee of The National Center for Health Statistics Ethics Review
Board. All participants or parents/legal representatives signed the
consent form.
RESULTS
Subject characteristics. We have included 8,340 subjects
from the NHANES 2007–2012, from which 1,802 (22%) were
subjects aged 16 yr. Two sets of models for FeNO were
derived, one with the whole sample and one with a subgroup of
never smokers (n  6,101). The characteristics of the included
participants are shown in Table 1.
The final model, based on the whole sample and including
all explanatory variables, showed a better fit (GAICmales 6,874
and GAICfemales  7,135, the lower the better) than models
that included only age and height (GAICmales  7,177 and
GAICfemales  7,400), and a similar fit compared with a model
including age, height, and smoking status (GAICmales  6,915
and GAICfemales  7,125). The model derived from the never-
smokers sample, that included the variables height, age, and
race/ethnicity, showed the best fit of all tested models (GAICmales
4,442 and GAICfemales  5,444).
The models and their variables are shown in Table 2.
As an example, for a 19-yr-old woman, 165 cm tall, non-
smoker, Caucasian with no hay fever in the past 12 mo, with an
observed FeNO value of 35 ppb, one would first retrieve the
Mspline and Sspline from the lookup tables (available online),
in this case, 0.00209 and 0.025124, respectively. Next, the
predicted FeNO is calculated as follows: ln(FeNO) pre-
dictedM exp(1.60112 0.41884 ln(165) 0.10275
ln(19)  0. 00209)  exp (2.37)  10.7 ppb, the ULN 95th 
exp(ln(1  1.645  0.2318  0.235)/0.2318  ln(10.8)) 
22.2 ppb and the z-score  ((ln(35)/ln(10.14))0.2318  1)/
(0.2318  0.235)  2.08. Thus, the observed FeNO is to be
considered elevated.
Effects of explanatory variables. When compared with
healthy, nonsmoking, nonatopic, non-Hispanic whites, smok-
ing reduces FeNO values by 32.6% (95% CI 30.5%–34.9%) in
men and by 37.5% (95% CI 35.2%–39.7%) in women. In
addition, the included races/ethnicities have proportionally
higher FeNO compared with non-Hispanic whites; male non-
Hispanic blacks have FeNO increased by 3.6% (95% CI
1.3%–5.8%), male Hispanics by 3.3% (95% CI 1.3%–5.3%),
and male other/multi-racial by 18.4% (95% CI 15.3%–21.5%).
Table 1. Description of participants included in the derivation of reference equations for FeNO
Men Women
Whole sample Total (n  4,001) 16 yr (n  851) 16 yr (n  3,150) Total (n 4,339) 16 yr (n  949) 16 yr (n  3,388)
Age range, mean (min–max) 36.5 (6–79) 10.5 (6–15) 43.4 (16–79) 36.2 (6–79) 10.5 (6–15) 43.6 (16–79)
Height, cm 168.8 (14.6) 147.0 (18.0) 174.7 (7.8) 157.7 (11.6) 145.0 (15.0) 161.2 (7.1)
BMI, kg/cm2 26.2 (6.5) 19.6 (4.4) 28.0 (5.7) 26.7 (7.5) 20.3 (5.2) 28.4 (7.1)
Ethnicity, n (%)
Non-Hispanic white 1,587 (40) 300 (35) 1,287 (41) 1,656 (38) 293 (31) 1,363 (40)
Non-Hispanic black 821 (20) 160 (19) 661 (21) 970 (22) 233 (24) 737 (22)
Hispanic 1,242 (31) 317 (37) 925 (29) 1324 (31) 340 (36) 984 (29)
Other/multiracial 351 (9) 74 (9) 277 (9) 389 (9) 85 (9) 304 (9)
Smoker, n (%) 495 (12) NA 495 (16) 373 (9) NA 373 (11)
Hay fever, n (%) 396 (10) 73 (9) 323 (10) 492 (11) 79 (8) 413 (12)
FeNO (ppb), geo. mean (Q1–Q3) 12.9 (8.5–19.5) 9.1 (6.5–13.0) 14.1 (10.0–21.0) 11.1 (7.5–16.0) 9.0 (6.5–12.5) 11.7 (8.0–17)
Never smokers Total (n 2,676) 16 yr (n  851) 16 yr (n  1,825) Total n  3,389 16 yr n  949 16 yr n  2,440
Age range, mean (min–max) 29.8 (6–79) 10.5 (6–15) 38.8 (16–79) 32.8 (6–79) 10.4 (6–15) 41.5 (16–79)
Height, cm 165.9 (17.6) 147.0 (18.0) 174.7 (7.8) 156.4 (12.3) 145.0 (15.0) 160.8 (7.2)
BMI, kg/cm2 25.2 (6.6) 19.6 (4.4) 27.8 (5.8) 26.1 (7.6) 20.3 (5.2) 28.3 (7.2)
Ethnicity, n (%)
Non-Hispanic white 1,006 (38) 300 (35) 706 (39) 1,146 (34) 293 (31) 853 (35)
Non-Hispanic black 555 (21) 160 (19) 395 (22) 769 (23) 232 (24) 537 (22)
Hispanic 874 (33) 317 (37) 557 (30) 1,126 (33) 339 (36) 787 (32)
Other/multiracial 241 (9) 74 (9) 167 (9) 348 (10) 85 (9) 263 (11)
Hay fever, n (%) 258 (10) 73 (9) 185 (10) 370 (11) 79 (8) 291 (12)
FeNO (ppb), geo. mean (Q1–Q3) 12.9 (9.5–19.5) 9.1 (6.5–13.0) 15.1 (10.5–21.5) 11.3 (7.5–16.0) 9.0 (6.5–12.5) 12.5 (8.5–17.5)
Values are means (SD). BMI, body mass index; FeNO, fraction of exhaled nitric oxide; NA, not available; ppb, parts per billion; Q1/3, Quartile 1/3.
Table 2. Regression coefficients for ln(FeNO) for calculating M, S, and L for men and women, respectively
Coefficients
M S L
Men Women Men Women Men Women
Never smokers (n  6,065)
Intercept a0 2.3332 1.6649 p0 0.9590 1.0151 q0 0.4836 0.5863
Height a1 0.5694 0.4333
Age a2 0.1041 0.1013 p1 0.1774 0.1645 q1 0.4517 0.4129
Non-hispanic black a3 0.0225 0.0339 p2 0.1108 0.1306
Hispanic a4 0.0426 0.0227 p3 0.0678 0.0797
Other/multiracial a5 0.0767 0.0489 p4 0.0535 0.0375
 Mspline Mspline  Sspline Sspline  Lspline Lspline
Whole sample (n  8,340)
Intercept a0 2.1279 1.60112 p0 1.00682 1.0175 q0 1.00682 1.01752
Height a1 0.5278 0.41884
Age a2 0.1021 0.10275 p1 0.15394 0.1544 q1 0.42066 0.42892
Smoker a3 0.1955 0.23005 p2 0.27337 0.2778
Non-Hispanic black a4 0.0271 0.02752 p3 0.08516 0.0972
Hispanic a5 0.0555 0.03019 p4 0.06813 0.0612
Other/multiracial a6 0.0913 0.04835 p5 0.09938 0.0228
 Mspline Mspline  Sspline Sspline  Lspline Lspline
Contributions of splines must be added to the calculated values; they are available in look-up tables. FeNO, fraction of exhaled nitric oxide; L, skewness; ln,
natural logarithm; M, expected mean; S, expected coefficient of variation.
Female non-Hispanic blacks have FeNO increased by 3.6%
(95% CI 1.4%–5.7%), and female other/multi-racial by 4.3%
(95% CI 1.4%–7.2%). The overall model for predicted FeNO
and ULN 95th in the entire age range, stratified by gender, is
shown in Fig. 1.
Furthermore, men have slightly higher FeNO values than
women, 15.7 ppb (95% CI 8.5–19.5) versus 13.3 ppb (95% CI
7.5–16.0), independent of age and race/ethnicity (Table 3).
This difference was consistent in adults, whereas there was no
significant difference in FeNO between boys and girls among
children less than 12 yr old, 9.3 ppb (95% CI 5.5–11.0) versus
9.8 ppb (95% CI 6.0–12.0). The ULN 95th for FeNO is also
significantly lower in boys aged 12 yr old compared with
adult men, 19.5 ppb (95% CI 15.3–23.2) versus 36.3 ppb (95%
CI 32.7–40.8), whereas this was not seen in women 22.1 ppb
(95% CI 17.5–26.1) versus 29.7 ppb (95% CI 27.0–32.9).
Comparison with recommended absolute cutoffs. Figure 2
shows the proportion of individuals with FeNO ULN 95th or
ULN 90th and ULN 95th or ULN 90th in the groups with
low FeNO (25 ppb, 20 ppb in children), intermediate
FeNO (25–50 ppb, 20–35 ppb in children), and high FeNO
(50 ppb, 35 ppb in children), as defined by the ATS
guidelines (12). There were 743 subjects classified in the
intermediate FeNO category (25–50 ppb in adults and 20–35
ppb in children), where the highest proportion of disagreement
between the classification of the 2011 recommendations occurs
with 34% (ULN 90th) or 63% (ULN95th) being classified
as having normal FeNO. The overall Cohen’s unweighted
kappa (95% CI) is 0.67 (0.65–0.69).
Comparison with multiple linear regression models. The
comparison of the LMS model with the linear models published
by See et al. (36) and Torén et al. (41) is shown in Table 4. The
model from Torén et al. was derived from a sample of indi-
viduals with an age range of 25–75 yr, and thus no values for
adolescents are presented. The model from See et al. does not
allow for the calculation of an individual ULN.
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Fig. 1. Predicted values and upper limit of normal at the 95th percentile for fraction of exhaled nitric oxide (FeNO) obtained with the model created using the
lambda-mu-sigma method and stratified by sex (male vs. female) and race (non-Hispanic whites vs. others). ppb, parts per billion.
Table 3. Predicted FeNO and ULN by using the LMS method applied on NHANES subjects, stratified by age and sex
Men Women
12 yr 12 yr All ages 12 yr 12 yr All ages
Never-smokers sample (n  547) (n  2,140) (n  2,687) (n  629) (n  2,785) (n  3,414)
Observed values, ppb‡ 9.3 (5.5–11.0) 14.7 (10.5–21.0) 12.9 (8.5–19.5) 9.8 (6.0–12.0) 12.1 (8.5–17.0) 11.3 (7.5–16.0)
Predicted values, ppb‡ 7.4 (6.2–8.7) 14.8 (13.5–16.3) 12.8 (11.7–15.9) 7.3 (6.7–8.8) 12.0 (10.7–13.4) 11.1 (9.99–12.8)
Predicted ULN 95th, ppb‡ 19.1 (15.8–23.2) 37.2 (34.0–40.7) 32.5 (30.9–39.6) 21.5 (17.8–25.5) 30.2 (27.4–33.0) 28.4 (26.1–32.2)
Whole sample (n  547) (n  3,439) (n  3,986) (n  629) (n  3,679) (n  4,308)
Observed values, ppb‡ 9.3 (5.5–11.0) 16.7 (9.5–20.5) 15.7 (8.5–19.5) 9.8 (6.0–12.0) 13.9 (8.0–17.0) 13.3 (7.5–16.0)
Predicted values, ppb‡ 7.4 (6.1–8.7) 14.3 (12.9–16.2) 13.4 (10.5–15.9) 7.8 (6.6–9.0) 11.8 (10.5–13.2) 11.2 (9.9–12.8)
Predicted ULN 95th, ppb‡ 19.5 (15.3–23.2) 36.3 (32.7–40.8) 34.0 (28.3–40.0) 22.1 (17.5–26.1) 29.7 (27.0–32.9) 28.6 (25.8–32.4)
FeNO, fraction of exhaled nitric oxide; LMS, lambda-mu-sigma; ppb, parts per billion; Q1/3, quartile 1/3; ULN 95th, Upper limit of normal (95th percentile).
‡Geometric mean (Q1–Q3).
DISCUSSION
In this study, we present reference equations for FeNO,
created with the LMS method, a robust methodological and
statistical approach. The explanatory variables of the equa-
tions, separate for men and women, were age, height, smoking
habits, and race/ethnicity, which are the most commonly re-
ported individual factors influencing FeNO (15). A significant
proportion of individuals with FeNO below the ULN given by
the LMS models are classified as having intermediate levels by
the 2011 ATS recommendations (12).
The derived equations were created using the LMS method,
which has previously been used in the construction of growth
charts in children (9). More recently, it was used in new
reference equations for lung function, which provided pre-
dicted values and age-corrected lower limits of normal for
spirometry in a wide range of ages (31). Furthermore, this
method allows for the modeling of the expected mean, ac-
counting for complex effects of explanatory variables on the
dependent variable with splines, which, in turn, allows for the
dependent variable to vary smoothly (i.e., nonlinearly) as a
function of an explanatory variable. Thus, the main advantage
of this method was the development of a continuous, smooth fit
over a wide age range (31, 32). Given the nonlinear effect of
age on FeNO, as previously described (17), and the previous
use of statistical models that does not account for the nonlin-
earity of the dependent variable (15, 36), it seemed reasonable
to apply the LMS method on FeNO.
The formation of NO is a complex and energy-consuming
biological process (3) that is seen already at birth (25), sug-
gesting that airway NO formation is important in humans and,
consequently, should normally be under strict biological con-
trol. The origin of NO in the airway epithelium, produced by
inducible NO synthase, indicates that the total surface area of
the airway mucosa will be an important determinant of FeNO.
Indeed, the airway diffusing capacity for NO, which theoreti-
cally should be dependent on the airway mucosal surface area,
has been shown to correlate with the anatomic dead space
volume in healthy children (28). Thus, it is logical to assume
that age, height, and gender are important factors when eval-
uating FeNO values, as seen for lung function parameters (17).
This has also been demonstrated previously with linear regres-
sion models for FeNO (11, 22, 27, 41).
However, the effect of race on FeNO is less established
(34); current data are inadequate to allow conclusions con-
cerning people of different genetic backgrounds. The prac-
tice of “race correction” or “ethnic adjustment” of predicted
lung-function values derived from reference equations is
still recommended and may be the best approximation for
current estimation of a “normal” lung function in a well-
defined population (35). Regarding FeNO, despite some
evidence on the influence of race/ethnicity in specific pop-
ulations (16, 20), it is still difficult to establish a common
ground of understanding, or at least one that can be easily
validated when comparing populations (15).
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Fig. 2. Proportion of individuals with predicted fraction of exhaled nitric oxide (FeNO) upper limit of normal at the 90th percentile (ULN 90th) and ULN
90th (A) and ULN 95th and ULN 95th (B) classified as having low FeNO, intermediate FeNO, and high FeNO, according to the 2011 American Thoracic
Society recommendations (12). The absolute number of subjects in each category is presented above each bar. There were 89% of subjects in the low FeNO group,
10% in the intermediate group, and 1% in the high group. ppb, parts per billion.
Table 4. Comparison of predicted FeNO and ULN 95th of the LMS model with previously published models
See et al. 2011 (36) Toren et al. 2017 (41) LMS Model
Predicted ULN 95th Predicted ULN 95th Predicted ULN 95th
Male, 15.5 y, 172 cm 13.9 NA NA NA 11.4 24.1
Male, 61.3 y, 173 cm 16.6 NA 18.9 42.8 14.3 30.3
Female, 13.9 y, 160 cm 11.0 NA NA NA 10.0 20.7
Female, 44.5 y, 162 cm 12.7 NA 13.7 29.0 12.0 25.0
All subjects were considered nonsmokers and nonatopics. In Toren et al., atopy was objectively confirmed with Phadiatop. Values in parts per billion. FeNO,
fraction of exhaled nitric oxide; LMS, lambda-mu-sigma; NA, not available; ULN 95th, upper limit of normality (95th percentile).
Cigarette smoking has long been known to reduce FeNO in
healthy subjects (30), and there are multiple mechanisms
proposed to explain this effect on FeNO. For example, lower
levels of IFN- and IFN--expressing cells in the airways of
smokers than in nonsmokers (21, 26, 42), and the reduction of
L-arginine bioavailability in the mucosa through the upregula-
tion of epithelial arginase-1 (5), may explain reduced FeNO in
present smokers (18).
The LMS models’ predicted values were slightly lower than
the observed values in both men and women, which may be
due to the skewed distribution of FeNO. However, these
differences were not statistically significant. The ULN was
higher in men than women, as expected (17). It is of note that
the ULN of FeNO in children below the age of 12 yr was
similar to the proposed fixed cutoffs of 20 ppb for the likely
absence of eosinophilic airway inflammation and benefit of
inhaled corticosteroids (12), 19.5 ppb in boys and 22.1 ppb in
girls, although the predicted FeNO is dependent on age (or
height) also in this age group (14). However, this was not the
case in adults or when considering the overall population, with
limits above the suggested 25 ppb: 36.3 ppb in men and 29.7
ppb in women. This difference was statistically significant and
is probably due to the known changes in FeNO throughout the
human age range. We have previously shown that there are two
significant points of change in the FeNO evolution throughout
the human age range, at the ages of ~16 and 61 yr in men and
14 and 45 yr in women, thus, both occurring after the age of 12
yr (17). The fixed cutoffs (12) do not fully account for these
changes, whereas the proposed models do. This fact is shown
by the poor agreement between the ULN and the recommended
categories of low FeNO (25 ppb, 20 ppb in children),
intermediate FeNO (25–50 ppb, 20–35 ppb in children), and
high FeNO (50 ppb, 35 ppb in children), regardless of
using the 90th or 95th percentile. The high cutoffs of 50 ppb or
35 ppb (children) in the ATS guidelines (12) are recommended
to be used for ruling in eosinophilic airway inflammation and
a high likelihood of a clinical response to inhaled corticoste-
roids. However, it may be more important to be able safely to
rule out airway inflammation in patients with asthma or sus-
pected asthma, and we found that 63% of individuals below
ULN 95th were classified as having an intermediate FeNO,
which may impair the initial assessment of patients with
respiratory symptoms.
The LMS models presented in this study show lower pre-
dicted values and ULN when compared with the models by See
et al. and Torén et al. This may be expected, given the fact that
linear models may not be the best approach to accommodate
the nonlinear evolution of FeNO with age, and the chosen age
points for the example subjects were at the ages where the
largest deviation between the models is expected. In addition,
the LMS model should theoretically be better at dealing with
the skewed distribution of FeNO in each age stratum. Further-
more, the advantage of the LMS model is that predicted values
and ULNs can be calculated from a single model, whereas See
et al. (36) had two different models for children aged 6–11 yr
and adults 12–80 yr, respectively. As far as we are aware, this
is the first description of predicted FeNO and ULN in the
whole age range of 6–80 yr.
One limitation of the present study is the lack of reliable
information on atopy. Future development of FeNO reference
equations should include an objective marker of IgE sensitiza-
tion. However, it may be difficult to capture the effect of atopy
in a dichotomous fashion since atopy may result in an increase
in FeNO of anywhere between 0 and more than 100 ppb,
depending on the degree of IgE sensitization and the level of
allergen exposure (3). Furthermore, the much better fit in the
never-smoker sample indicates that the effect of smoking is
also highly variable, but this factor could possibly be improved
by using an objective marker of the degree of cigarette smoke
exposure. However, these limitations do not rule out the benefit
of adjusting for the more easily predictive effect of, for exam-
ple, age, height, and gender, on expected normal FeNO values
(7, 11) since these factors have a similar impact on FeNO in
healthy subjects and patients with asthma (2). We have previ-
ously shown in a systematic review that FeNO may be higher
in children with atopy as well as in children with allergic
rhinitis, whereas in adults, an increase has only been observed
in allergic rhinitis, with FeNO being similar in atopic and
healthy individuals (23). However, there is no reliable infor-
mation on rhinitis in NHANES subjects (8).
In conclusion, we suggest a novel model for the prediction
of reference FeNO values that can contribute to the interpre-
tation of FeNO in clinical practice, adapted to each individual
subject, and adjusted for explanatory variables. This is an
approach similar to the current paradigm of reference values in
spirometry (31). The model should be further validated in large
samples of subjects with an objective measurement of atopy
and a medical diagnosis of asthma and rhinitis.
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